A missing gene is linked to shorter survival in some glioblastoma patients
Original title: CDKN2A deletion associated with poor prognosis in patients with TERT promoter wild-type, IDH wild-type glioblastoma.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This study only looked back at past patient records, so it is not a treatment you can get.
The short version
In one group of brain tumor patients, a missing gene was tied to living a shorter time.
What was studied. Doctors looked back at the records of 112 people with glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary. All of their tumors were IDH gene change: A small change in a tumor's IDH gene. It is the first thing your team looks at when naming an adult glioma, and it can affect which treatments are offered. Your pathology report says whether your tumor has it. See the glossary wild-type. The team compared tumor gene tests with how long people lived.
What they found. Of the 112 people, 70 (62.5%) had a change in the TERT promoter mutation: A change in the switch that controls the TERT gene. It keeps tumor cells from aging out. It is one of several findings your team reads together to name the tumor. See the glossary promoter. Tumors with and without that change had different gene patterns. People whose tumors were missing the CDKN2A gene lived a shorter time. That link was clear in people without the TERT promoter change. It was not seen in people who had that change.
What this means, and what it doesn't
What it could mean: Tumor gene tests may help a doctor talk about what to expect. Two people with the same tumor name can have very different outlooks. You can ask your care team what your own tumor tests showed.
What it doesn't mean: This is not a new treatment, and it is not a cure. It is not a promise about any one person. The study only looked back at records from a small group of people. It does not prove the missing gene is what shortens survival. Nothing here changes the care you can get today.
Source: PubMed, October 10, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.